Shorla Oncology’s Cancer Treatment Approved by FDA

The NDA for TEPYLUTE, an innovative medication used to treat breast and ovarian cancer, has been authorised by the FDA for specialty pharmaceutical business Shorla Oncology.

The drug, formerly known as SH-105, is an injection that is ready to dilute, making preparation easier and guaranteeing accurate dose for therapies for ovarian and breast cancer.

Shorla Oncology chief commercial officer Rayna Herman commented: “Among TEPYLUTE’s many benefits, it removes the necessity to reconstitute which can introduce additional risks of drug preparation errors.

Another addition to Shorla Oncology’s repertoire is SH-201, an appealing oral liquid therapy for specific forms of leukaemia and other malignancies.

SH-201 has been approved by the FDA for NDA assessment in April 2024, and the decision to approve it is expected by November 30.

Addressing orphan and paediatric malignancies, the business’s pipeline of oncology medicines aims at tackling unmet needs, medication shortages, and inadequate applicability for the targeted groups.